4956-05-2

Basic information

• Product Name: 5-Bromo-6-azauracil
• Synonyms: VITAS-BB TBB000521;4h)-dione,6-bromo-as-triazine-5(2h;5-BROMO-6-AZAURACIL;6-BROMO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-3,5-DIONE;6-BROMO-2H-[1,2,4]TRIAZINE-3,5-DIONE;6-BROMO-1,2,4-TRIAZINE-3,5(2H,4H)-DIONE;AURORA 14997;IFLAB-BB F1207-0035
• CAS NO: 4956-05-2
• Molecular Formula: C₃H₂BrN₃O₂
• Molecular Weight: 191.97
• Product Categories: Heterocycles series;Halides;Ring Systems
• Mol File: 4956-05-2.mol

Chemical Properties

• Appearance: /
• Density: 2.61 g/cm³
• Refractive Index: 1.831
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 6.11±0.40(Predicted)
• CAS DataBase Reference: 5-Bromo-6-azauracil(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-6-azauracil(4956-05-2)
• EPA Substance Registry System: 5-Bromo-6-azauracil(4956-05-2)

Safety Data

• Hazardous Substances Data: 4956-05-2(Hazardous Substances Data)

Usage

Uses

Used in Cancer Therapy Research:
5-Bromo-6-azauracil is used as a potential anticancer agent for its ability to inhibit the proliferation of cancer cells. Its mechanism of action involves the competitive inhibition of UPRT, which can lead to disruptions in nucleotide metabolism, thereby affecting the growth and survival of cancer cells.
Used in Nucleotide Metabolism Studies:
In the field of biochemical research, 5-Bromo-6-azauracil is utilized as a tool to study the mechanisms of nucleotide salvage pathways. By inhibiting UPRT, it provides insights into how cells manage and recycle nucleotides, which is crucial for understanding cellular metabolism and identifying potential drug targets for therapeutic intervention.
Used in Drug Development:
5-Bromo-6-azauracil may be employed in the development of new pharmaceuticals targeting cancer treatment. Its unique ability to interfere with nucleotide metabolism could lead to the creation of drugs that are more effective against certain types of cancer, especially when used in combination with existing therapies.
Used in Biochemical Education:
As a compound that interacts with key enzymes in nucleotide metabolism, 5-Bromo-6-azauracil can be used in educational settings to illustrate the principles of enzyme inhibition and the role of nucleotides in cellular processes.
Used in Molecular Biology:
5-Bromo-6-azauracil may also find applications in molecular biology for studying gene expression and regulation, given its impact on nucleotide availability, which is essential for DNA and RNA synthesis.

InChI:InChI=1/C3H2BrN3O2/c4-1-2(8)5-3(9)7-6-1/h(H2,5,7,8,9)

Upstream product

• 461-89-2 6-azauracil 

Downstream Products

• 873-41-6 3,5,6-trichlorotriazine 
• 170872-48-7 1-(3-benzyloxy-2-hydroxypropyl)-5-bromo-6-azauracil 
• 4956-10-9 3.5-Dihydroxy-6-<2-amino-1.3.4-thiadiazolyl-(5)-mercapto>-1.2.4-triazin 
• 4956-12-1 3,5-Dihydroxy-6-morpholino-1,2,4-triazin 
• 1562525-86-3 6-bromo-2-(4-phenoxyphenethyl)-1,2,4-triazine-3,5(2H,4H)-dione 
• 1562525-94-3 6-bromo-2-(3-phenoxyphenethyl)-1,2,4-triazine-3,5(2H,4H)-dione 

Relevant articles and documents

Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity

A series of 1,3,5-triazinic inhibitors of focal adhesion kinase (FAK) has recently been shown to exert antiangiogenic activity against HUVEC cells and anticancer efficacy against several cancer cell lines. In this report, we designed and synthesized a series of new compounds containing a 1,2,4-triazine core as novel scaffold for FAK inhibitors. These compounds displayed 10?7?M IC50 values, and the best one showed IC50 value of 0.23?μM against FAK enzymatic activity. Among them, several inhibitors potently inhibited the proliferation of glioblastoma (U-87MG) and colon (HCT-116) cancer cell lines. Docking of compound 10 into the active site of the FAK kinase was performed to explore its potential binding mode.

Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells

Neddylation modification is often over-expressed in a variety of human tumor cells. Therefore, targeting neddylation pathway may represent a potential approach to the treatment of human tumors. Herein, we describe the discovery of a hit scaffold from our

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Picornaviridae and/or Flaviviridae viral infections with one or more nucleotide analogs.

BICYCLIC COMPOUNDS

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

Synthesis of novel 3-substituted-5H-benzo[5,6][1, 4]thiazino[3,2-e][1,2,4]triazines and their 15-lipoxygenase inhibitory activity

A new group of 3-substituted-5H-benzo[5,6][1,4]thiazino[3,2-e][1,2,4]triazines was designed, synthesized and evaluated as inhibitors of 15-lipoxygenase (15-LO), and the results were compared with those of standard ligand 4-methyl-2-(4-methylpiperazin-1-yl)pyrimido[4,5-b][1,4]benzothiazine (4-MMPB). Among the newly designed ligands, compound 9e showed the best IC50 of 15-LO inhibition (IC50?=?38?μM). The docking calculations were performed in MOE software based on the function of force-field scoring, in order to study the interaction of these new compounds and standard ligand with 15-LO. The docking study implied that these ligands have hydrogen bond interaction with the residue of active site of 15-LO.

NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS

There is provided compounds of formula (I), wherein A1, A4, A4a, A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS

There is provided compounds of formula (I), wherein A1, A4, A4a,A5, B1, B1a, B2, B2a, B3, B3a, B4, B4a and R3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS

The present invention relates to derivatives of general formula I wherein : - W represents nitrogen, - R1 represents: ? a hydrogen or a linear or branched C1-C5 alkyl radical or, ? a C1-C3 alkyl radical substituted with groups such as trifluoromethyl, nitrile, hydroxy, C1-C3 alcoxy, C3-C6 alkoxyalkoxy, indolyl, thiophenyl, oxothiophenyl, C1-C3 N-alkylcarbamoyl groups or, ? a phenyl or pyridyl or naphthyl, or thiophenyl group optionally substituted with one or more groups such as halogen atoms, nitro, nitrile, trifluoromethyl, vinyl, methylsulfanyl, linear branched C1-C4 alkyl, linear or branched C1-C3 alkoxy groups, ? a C6 2-oxocycloalkyl radical - R2 represents a methyl or heptyl, - m, n are equal to 1, - V represents CH2, - X-Y represents -N- (C=O) -, -CH-O-, - Z represents a phenyl group substituted with one or more trifluoromethyl groups, halogen atoms or linear C1-C4 alkyl groups.

NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS

The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating or preventing diseases or disorders, including treatment of anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, panic disorder, posttraumatic stress disorders, urge urinary incontinence, gastroesophageal reflux disease, transient lower oesophageal sphincter relaxations, functional gastrointestinal disorders and irritable bowel syndrome.

AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS

The present invention relates to novel compounds of formula (I) or a salt thereof, wherein G is selected from a group consisting of: phenyl, a 5- or 6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; p is an integer